Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887350 | 0.91 | CTNNB1 (0.48) | ALDH1A1SMN1; SMN2CHRM3CTNNB1TCF7L2 | |
| SCHEMBL5886749 | 0.90 | MCHR1 (0.54) | ALDH1A1GAASMN1; SMN2CHRM3CTNNB1 | |
| SCHEMBL5886974 | 0.89 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2LMNAHTTHPGD | |
| SCHEMBL5887090 | 0.87 | CTNNB1 (0.47) | ALDH1A1SMN1; SMN2CHRM3CTNNB1TCF7L2 | |
| SCHEMBL5886714 | 0.86 | ALDH1A1 (0.45) | ALDH1A1GAASMN1; SMN2LMNAMEN1 | |
| SCHEMBL5886982 | 0.85 | CTNNB1 (0.51) | ALDH1A1SMN1; SMN2CHRM3CTNNB1TCF7L2 | |
| SCHEMBL5886825 | 0.85 | NPC1 (0.45) | ALDH1A1GAASMN1; SMN2LMNAMEN1 | |
| SCHEMBL5887644 | 0.85 | NPC1 (0.45) | ALDH1A1GAASMN1; SMN2LMNAMEN1 | |
| SCHEMBL5886766 | 0.85 | NPC1 (0.45) | ALDH1A1GAASMN1; SMN2LMNAMEN1 | |
| SCHEMBL5886765 | 0.85 | MAPT (0.48) | ALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | ALDH1A1 1860/4885GAA 2823/4885SMN1; SMN2 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.